Experience with Vancomycin in Patients Receiving Slow Low-Efficiency Dialysis

Hospital Pharmacy

Volumn 39, Issue 2, 2004, Pages 138-143

  Ahern, John W ^a   Lai, Cecilia ^a,b   Rebuck, Jill A ^a   Possidente, Carl J ^c   Weidner, Mark ^a  

^a FLETCHER ALLEN HEALTH CARE   (United States)

^b Department of Phamacotherapy ^*

^c PFIZER INC   (United States)

Author keywords

Dialysis; Pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HEMODIALYSIS; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; SLOW LOW EFFICIENCY DIALYSIS; SURGICAL PATIENT;

EID: 1042279534     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870403900208     Document Type: Article

References (31)

1. Bierman MH, Needham-Walker CA, et al. Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients. J Dial. 1980;4:179-84.
2. Cunha BA, Quintiliani R, Deglin JM, et al. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis. 1981;3:S269-S72.
3. Alwakeel J, Najjar TA, al-Yamani MJ, et al. Comparison of the effects of three haemodialysis membranes on vancomycin disposition. Int Urol Nephrol. 1994;26:223-8.
4. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: Kinetic model and comparison of four membranes. Am J Kidney Dis. 1992;20:354-60.
5. Pollard TA, Lampasona V, Akkerman S, et al. Vancomycin redistribution: Dosing recommendations following high-flux hemodialysis. Kidney Int. 1994;45:232-7.
6. Touchette MA, Patel RV, Anandan JV, et al. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis. 1995;26:469-74.
7. Welage LS, Mason NA, Hoffman EJ, et al. Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics. J Am Soc Nephrol. 1995;6:1284-90.
8. Vanholder R, Van Biesen W, Lameire N. What is the renal replacement method of first choice for intensive care patients? J Am Soc Nephrol. 2001;12:S40-3.
9. Marshall MR, Golper TA, Shaver MJ, et al. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int. 2001;60:777-85.
10. Amerling R, Caraiani NS, Hafeez T, et al. CVVHD with modified fresenius 2008H: Initial experience [Abstract]. J Am Soc Nephrol. 1988;9:166A.
11. Schlaeper C, Amerling R, Manns M, et al. High clearance continuous renal replacement therapy with a modified dialysis machine. Kidney Int. 1999;72:S20-3.
12. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet. 1995;28:327-42.
13. Rodvold KA, Everett JA, Pryka RD. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet. 1997;33:32-51.
14. Bourget P, Fernandez H, Delouis C, et al. Transplacental passage of vancomycin during the second trimester of pregnancy. Obstet Gynecol. 1991;78:908-11.
15. Boucher BA, Kuhl DA, Hickerson WL. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis. 1992;14:458-63.
16. Aldaz A, Ortega A, Idoate A, et al. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit. 2000;22:250-7.
17. Wilhelm MP, Estes L. Vancomycin. Mayo Clin Proc. 1999;74:928-35.
18. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25:433-7.
19. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32:848-52.
20. Thomson AH, Grant AC, Rodger RSC, et al. Gentamicin and vancomycin removal by continuous venovenous hemofiltration. Ann Pharmacother. 1991;25:127-9.
21. Dupuis RE, Matzke GR, Maddux FW, et al. Vancomycin disposition during continuous arteriovenous hemofiltration. Clin Pharm. 1989;8:371-4.
22. Davies SP, Azadian BS, Kox WJ, et al. Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. Nephrol Dial Transplant. 1992;7:848-54.
23. Santre CH, Leroy O, Simon M, et al. Pharmacokinetics of vancomycin during continuous hemodiafiltration. Intensive Care Med. 1993;19:347-50.
24. Reetze-Beonorden P, Bohler J, Kohler C, et al. Elimination of vancomycin in patients on continuous arteriovenous hemodialysis. Contrib Nephrol. 1991;93:135-9.
25. Benet LZ. Pharmacokinetic parameters: which are necessary to define a drug substance? Eur J Respir Dis. 1984;65: S45-61.
26. Ackerman BH, Olsen KM, Padilla CB. Errors in assuming a one-compartment model for vancomycin. Ther Drug Monit. 1990;12:304-5.
27. Sawchuk RJ, Zaske DE, Cipolle RJ, et al. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther. 1977;21:362-9.
28. Murphy JE, Winter ME. Clinical pharmacokinetic pearls: Bolus versus infusion equations. Pharmacotherapy. 1996;16:698-700.
29. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis. 1994;18:533-43.
30. Mollering RC. Monitoring serum vancomycin levels: Climbing the mountain because it is there? Clin Infect Dis. 1994;18:544-6.
31. Smith PF, Morse GD. Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease. Ann Pharmacother. 1999;33:1329-33.